Allena Pharmaceuticals EBITDA 2011-2026 | ALNA

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Allena Pharmaceuticals

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-47.3 M	-31.8 M	-46.8 M	-35.5 M	-20.9 M	-24.1 M	-13.8 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-13.8 M	-47.3 M	-31.5 M

Quarterly EBITDA Allena Pharmaceuticals

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-6.68 M	-11.4 M	-10.1 M	-12.4 M	-13.5 M	-11.3 M	-9.98 M	-7.8 M	-6.48 M	-7.48 M	-11.3 M	-13.2 M	-11.3 M	-11.5 M	-9.78 M	-9.66 M	-8.11 M	-7.95 M	-6.57 M	-4.31 M	-4.44 M	-5.52 M	-6 M	-6.07 M	-7.04 M	-5.04 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-4.31 M	-13.5 M	-8.66 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Nymox Pharmaceutical Corporation NYMX	-12.5 M	-	-19.68 %	$ 18.4 M	Canada
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	1.19 M	$ 0.9	-2.33 %	$ 6.62 M	China
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	232 M	$ 21.96	-0.68 %	$ 3.64 B	USA
RedHill Biopharma Ltd. RDHL	-81.1 M	$ 1.02	-0.49 %	$ 428 M	Israel
Allakos ALLK	-190 M	-	-	$ 28.6 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Aligos Therapeutics ALGS	-87.1 M	$ 6.4	4.4 %	$ 63.3 M	USA
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Aridis Pharmaceuticals ARDS	-29.5 M	-	17.91 %	$ 11.1 M	USA
Avenue Therapeutics ATXI	-3.08 M	-	-52.27 %	$ 4.45 M	USA
Amphastar Pharmaceuticals AMPH	172 M	$ 21.41	1.9 %	$ 1 B	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain
BioDelivery Sciences International BDSI	37.3 M	-	-4.8 %	$ 255 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Brainstorm Cell Therapeutics BCLI	-9.75 M	-	-2.5 %	$ 5.88 M	USA
Kazia Therapeutics Limited KZIA	-7.74 M	$ 12.26	3.72 %	$ 1.62 B	Australia
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
BioNTech SE BNTX	15.3 B	$ 105.46	-0.09 %	$ 27.2 B	Germany
BeiGene, Ltd. BGNE	589 M	-	0.49 %	$ 251 B	Cayman-islands
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	-70.5 M	$ 4.08	0.25 %	$ 436 M	USA
Arcutis Biotherapeutics ARQT	-11.5 M	$ 23.26	1.75 %	$ 2.96 B	USA
Cara Therapeutics CARA	-26.7 M	-	-3.03 %	$ 260 M	USA
Autolus Therapeutics plc AUTL	-262 M	$ 1.44	-5.88 %	$ 383 M	Britain
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
BioXcel Therapeutics BTAI	-50.2 M	$ 1.06	-3.64 %	$ 12.9 M	USA
CASI Pharmaceuticals CASI	-41.4 M	-	-	$ 35.4 M	USA
AVROBIO AVRO	10.8 M	-	1083.1 %	$ 745 M	USA
Cabaletta Bio CABA	-171 M	$ 2.95	-3.28 %	$ 296 M	USA
Can-Fite BioPharma Ltd. CANF	-9.93 M	$ 2.91	-1.36 %	$ 4.79 M	Israel
bluebird bio BLUE	-216 M	-	-	$ 546 M	USA
CymaBay Therapeutics CBAY	-101 M	-	-	$ 3.45 B	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA